Sign in
Register
IC Journals Master List
IC Conferences
IC Journals Master List 2011
Submission Menu
Archives
|
IndexCopernicus Journal Abstract
| |
| A double-blind, randomized, prospective evaluation of the efficacy and safetyof risperidone versus haloperidol in the treatment of schizoaffective disorder. P G Janicak, P E Keck, J M Davis, J W Kasckow, K Tugrul, S M Dowd, J Strong, R P Sharma, S M Strakowski Journal of Clinical Psychopharmacology 2002; 21(4):360-368 ICID: 436473 |
| Article type: Original article |
| IC™ Value: 15.05 |
| The relative efficacy and safety of risperidone versus haloperidol in thetreatment of schizoaffective disorder was studied. Sixty-two patients (29 depressed type; 33 bipolartype) entered a three-site, randomized, double-blind, 6-week trial of risperidone (up to 10 mg/day) orhaloperidol (up to 20 mg/day). Trained raters assessed baseline, weekly, and end-of-study levels of psychopathologywith the Positive and Negative Syndrome Scale (PANSS), the 24-item Hamilton Rating Scale for Depression(HAM-D-24) and the Clinician-Administered Rating Scale for Mania (CARS-M). The authors were unable tostatistically distinguish between risperidone and haloperidol in the amelioration of psychotic and manicsymptoms. In addition, there was no difference in worsening of mania between the two agents in eithersubgroup (i.e., depressed or bipolar subgroups). For the total PANSS, risperidone produced a mean decreaseof 16 points from baseline compared with a 14-point decrease with haloperidol. For the total CARS-M scale,risperidone and haloperidol produced mean change scores of 5 and 8 points, respectively, and for theCARS-M Mania subscale, 3 and 7 points, respectively. Additionally, risperidone produced a mean decreaseof 13 points from the baseline 24-item HAM-D, compared with an 8-point decrease with haloperidol. Inthose patients who had more severe depressive symptoms (i.e., HAM-D baseline score >20), risperidoneproduced at least a 50% mean improvement in 12 (75%) of 16 patients in comparison to 8 (38%) of 21 patientsreceiving haloperidol. Haloperidol produced significantly more extrapyramidal side effects and resultedin more dropouts caused by any side effect. There was no difference between risperidone and haloperidolin reducing both psychotic and manic symptoms in this group of patients with schizoaffective disorder.Risperidone did not demonstrate a propensity to precipitate mania and was better tolerated than haloperidol.In those subjects with higher baseline HAM-D scores (i.e., >20), risperidone produced a greater improvementin depressive symptoms than haloperidol. |
 |
ICID 436473 PMID 11476119 - click here to show this article in PubMed database |
Related articles |
| rewrite CAPTCHA to display the MeSH keywords |
|
|
|